Amicus Therapeutics Inc. (FOLD)

11.97
NASDAQ : Health Technology
Prev Close 12.29
Day Low/High 11.93 / 12.66
52 Wk Low/High 11.57 / 17.62
Avg Volume 2.37M
Exchange NASDAQ
Shares Outstanding 189.13M
Market Cap 2.32B
EPS -1.90
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

First Week Of January 2021 Options Trading For Amicus Therapeutics (FOLD)

First Week Of January 2021 Options Trading For Amicus Therapeutics (FOLD)

Investors in Amicus Therapeutics Inc saw new options become available this week, for the January 2021 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 850 days until expiration the newly available contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Here's My Take on Biotech Stocks

Here's My Take on Biotech Stocks

I think M&A activity will pick up markedly going forward across the industry.

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Alkermes Wins Quick Reversal From FDA on Antidepressant Drug

Two weeks ago, the agency told Alkermes it needed more trials for antidepressant drug candidate ALKS-5461. The agency, however, had a change of heart, sending shares jumping on the news.

Amicus Therapeutics Announces Approval Of Galafold® (Migalastat) For Fabry Disease In Japan

Amicus Therapeutics Announces Approval Of Galafold® (Migalastat) For Fabry Disease In Japan

First Amicus Medicine and First Oral Precision Medicine for Fabry Patients with an Amenable Mutation in Japan

Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives To Change People's Lives Living With Rare Diseases

Amicus Therapeutics Launches Healing Beyond Disease™ Initiatives To Change People's Lives Living With Rare Diseases

Unique Volunteerism, Mentorship, Giving, Global Access and Advocacy Programs Under Long-term Healing Beyond Disease Initiatives

U.S. FDA Files New Drug Application Under Priority Review For Migalastat For Treatment Of Fabry Disease

U.S. FDA Files New Drug Application Under Priority Review For Migalastat For Treatment Of Fabry Disease

Six-Month PDUFA Goal Date is August 13, 2018

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

2 Biotech Acquisition Candidates That Could Be Next in M&A Crosshairs

Outside of oncology, the rare disease area is a good target for M&A in 2018.

Circle These Biotech Acquisition Candidates

Circle These Biotech Acquisition Candidates

Outside of oncology, the rare disease area is a good target for M&A in 2018.

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

10 Biotech Stocks Investors Should Put on Their Shopping List for 2018

Biotech M&A activity will pick up markedly in 2018, and these companies are likely to be the most active in that space.

10 Biotech Stocks to Watch in 2018

10 Biotech Stocks to Watch in 2018

There are a variety of players that should be active in the M&A space next year.

Biotech Stocks to Watch: Part 1

Biotech Stocks to Watch: Part 1

Upcoming catalysts will redefine the biotech market -- and here are 3 names that will feel the impact.

Amicus Therapeutics Appoints Michael C. Diem, MD As Senior Vice President Of Business And Corporate Development

Amicus Therapeutics Appoints Michael C. Diem, MD As Senior Vice President Of Business And Corporate Development

Driven Business Executive with Strong Industry Track Record

TheStreet Quant Rating: D- (Sell)